Chronic urticaria and coagulation: Pathophysiological and clinical aspects

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 6, 2014, Pages 683-691

  Tedeschi, A ^a   Kolkhir, P ^b   Asero, R ^c   Pogorelov, D ^b   Olisova, O ^b   Kochergin, N ^b   Cugno, M ^d  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Ospedale 21   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

chronic urticaria; coagulation; eosinophil; thrombin; tissue factor

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; COMPLEMENT; THROMBIN; THROMBOPLASTIN;

ANGIOGENESIS; ANTICOAGULANT THERAPY; BLOOD CLOTTING; BLOOD LEVEL; BLOOD VESSEL PERMEABILITY; CHRONIC URTICARIA; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DEGRANULATION; ENDOTHELIUM CELL; EOSINOPHIL; EXPERIMENTAL MODEL; FIBRINOLYSIS; HISTAMINE RELEASE; HUMAN; MAST CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THROMBOCYTE VOLUME; VASODILATATION; ANIMAL; BLOOD; CHRONIC DISEASE; IMMUNOLOGY; METABOLISM; URTICARIA;

ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CHRONIC DISEASE; COMPLEMENT SYSTEM PROTEINS; EOSINOPHILS; HUMANS; THROMBIN; THROMBOPLASTIN; URTICARIA;

EID: 84899970448     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12389     Document Type: Review

References (95)

1. Juhlin L,. Reccurent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981; 104: 369-381.
2. Kaplan A, Horakova Z, Katz S,. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol 1978; 61: 350-354.
3. Hein R,. Chronic urticaria: impact of allergic inflammation. Allergy 2002; 57: S19-S24.
4. Gruber B, Baeza M, Marchese M, Agnello V, Kaplan AP,. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90: 213-217.
5. Grattan C, Sabroe R, Greaves M,. Chronic urticaria. J Am Acad Dermatol 2002; 46: 645-657.
6. O'Donnell BF, O'Neill CM, Francis DM, Niimi N, Barr RM, Barlow RJ, et al. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 853-858.
7. Cugno M, Marzano AV, Asero R, Tedeschi A,. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2009; 5: 97-101.
8. Asero R, Riboldi P, Tedeschi A, Cugno M, Meroni P,. Chronic urticaria: a disease at a crossroad between autoimmunity and coagulation. Autoimmun Rev 2007; 7: 71-76.
9. Cugno M, Tedeschi A, Crosti C, Marzano AV,. Activation of blood coagulation in autoimmune skin disorders. Expert Rev Clin Immunol 2009; 5: 605-613.
10. Cugno M, Tedeschi A, Asero R, Meroni PL, Marzano AV,. Skin autoimmunity and blood coagulation. Autoimmunity 2010; 43: 189-194.
11. Cugno M, Asero R, Tedeschi A, Lazzari R, Marzano AV,. Inflammation and coagulation in urticaria and angioedema. Curr Vasc Pharmacol 2012; 10: 653-658.
12. Schaeffer RC Jr, Gong F, Bitrick MS Jr, Smith TL,. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 1993; 264: H1798-H1809.
13. Ehringer WD, Edwards MJ, Miller FN,. Mechanisms of alpha-thrombin, histamine, and bradykinin induced endothelial permeability. J Cell Physiol 1996; 167: 562-569.
14. Asero R, Tedeschi A, Cugno M,. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152: 384-389.
15. Marzano AV, Tedeschi A, Berti E, Fanoni D, Crosti C, Cugno M,. Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol 2011; 165: 44-50.
16. Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213-3218.
17. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-179.
18. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M,. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 254-257.
19. Levi M,. The coagulant response in sepsis and inflammation. Hamostaseologie 2010; 30: 10-16.
20. Osterud B,. Tissue factor expression in blood cells. Thromb Res 2010; 125: S31-S34.
21. Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, Albrecht S, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007; 109: 995-1002.
22. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R,. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 2009; 148: 170-174.
23. Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F,. Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol 2005; 37: 628-636.
24. Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, et al. Plasma levels and skin-eosinophil expression of vascular endothelial growth factor (VEGF) in patients with chronic urticaria. Allergy 2009; 64: 1616-1622.
25. Dvorak HF, Brown LF, Detmar M, Dvorak AM,. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
26. Puccetti A, Bason C, Simeoni S, Millo E, Tinazzi E, Beri R, et al. In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 2005; 35: 1599-1607.
27. Asero R, Cugno M, Tedeschi A,. Eosinophils in chronic urticaria: supporting or leading actors? World Allergy Organ J 2009; 2: 213-217.
28. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G,. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004; 24: 271-281.
29. Lampinen M, Carlson M, Hakansson LD, Venge P,. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004; 59: 793-805.
30. Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M,. Serum eotaxin levels in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol 2012; 44: 188-192.
31. Bhattacharyya SP, Drucker I, Reshef T, Kirshenbaum AS, Metcalfe DD, Mekori YA,. Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact. J Leukoc Biol 1998; 63: 337-341.
32. Razin E, Marx G,. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984; 133: 3282-3285.
33. Dugina TN, Kiseleva EV, Glusa E, Strukova SM,. Activation of mast cells induced by agonists of proteinase-activated receptors under normal conditions and during acute inflammation in rats. Eur J Pharmacol 2003; 471: 141-147.
34. Dugina TN, Kiseleva EV, Chistov IV, Umarova BA, Strukova SM,. Receptors of the PAR family as a link between blood coagulation and inflammation. Biochemistry (Moscow) 2002; 67: 65-74.
35. Ossovskaya VS, Bunnett NW,. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579-621.
36. Kido H, Fukusen N, Katunuma M, Morita T, Iwanaga S,. Tryptase from rat mast cells converts bovine prothrombin to thrombin. Biochem Biophys Res Commun 1985; 132: 613-619.
37. Asero R, Tedeschi A, Riboldi P, Cugno M,. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-1117.
38. Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, Riboldi P, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007; 119: 705-710.
39. Wang F, Tang H, Xu JH, Kang KF,. Activation of the blood coagulation cascade is involved in patients with chronic urticaria. J Allergy Clin Immunol 2009; 123: 972-973.
40. Takeda T, Sakurai Y, Takahagi S, Kato J, Yoshida K, Yoshioka A, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011; 66: 428-433.
41. DeMichele MA, Moon DG, Fenton JW II, Minnear FL,. Thrombin's enzymatic activity increases permeability of endothelial cell monolayers. J Appl Physiol 1990; 69: 1599-1606.
42. Levi M, van der Poll T,. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15: 254-259.
43. Chu AJ,. Tissue factor mediates inflammation. Arch Biochem Biophys 2005; 440: 123-132.
44. Bauer KA, Weitz JI,. Laboratory markers of coagulation and fibrinolysis. In:, Colman RW, Hirsh J, Marder WJ, Salzman EW, editors. Hemostasis and Thrombosis: Principles and Clinical Practice. Philadelphia, PA: Lippincott; 1994: 1197.
45. Righini M, Perrier A, De Moerloose P, Bounameaux H,. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008; 6: 1059-1071.
46. Bork K, Witzke G, Artmann K, Benes P, Bockers M, Kreuz W,. Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria. Arch Dermatol Res 1984; 276: 375-380.
47. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M,. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008; 63: 176-180.
48. Fujii K, Usuki A, Kan-No Y, Ohgou N,. Elevation of circulating thrombin-antithrombin III complex and fibrin degradation products in urticaria. A laboratory finding unrelated to intravascular coagulopathy. J Dermatol 2008; 35: 308-310.
49. Khalaf AT, Liu XM, Sheng WX, Tan JQ, Abdalla A,. Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. J Eur Acad Dermatol Venereol 2008; 22: 487-492.
50. Yildiz H, Karabudak O, Dogan B, Harmanyeri Y,. Evaluation of autologous plasma skin test in patients with chronic idiopathic urticaria. Br J Dermatol 2011; 165: 1205-1209.
51. Zhu H, Liang B, Li R, Li J, Lin L, Ma S, et al. Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 2013; 31: 43-50.
52. Ver Elst K, Jochmans K, De Pauw A, De Waele M,. Plasma D-dimer concentrations in different clinical conditions. Acta Clin Belg 2002; 57: 325-330.
53. Criado PR, Antinori LC, Maruta CW, Reis VM,. Evaluation of D-dimer serum levels among patients with chronic urticaria, psoriasis and urticarial vasculitis. An Bras Dermatol 2013; 88: 355-360.
54. Triwongwaranat D, Kulthanan K, Chularojanamontri L, Pinkaew S,. Correlation between plasma D-dimer levels and the severity of patients with chronic urticaria. Asia Pac Allergy 2013; 3: 100-105.
55. Breier G, Albrecht U, Sterrer S, Risau W,. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentation. Development 1992; 114: 521-532.
56. Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M,. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64: 254-257.
57. Renne T,. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
58. Dewald G, Bork K,. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286-1289.
59. Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104.
60. Kasperska-Zajac A, Jasinska T,. Analysis of plasma D-dimer concentration in patients with delayed pressure urticaria. J Eur Acad Dermatol Venereol 2011; 25: 232-234.
61. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M,. Coagulation cascade and fibrinolysis in patients with multiple-drug allergy syndrome. Ann Allergy Asthma Immunol 2008; 100: 44-48.
62. Asero R, Tedeschi A, Cugno M,. Markers of autoreactivity, coagulation and angiogenesis in patients with nonallergic asthma. Allergy 2011; 66: 1339-1344.
63. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW,. A serological mediator in chronic idiopathic urticaria-a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114: 583-590.
64. Grattan CE, Francis DM, Hide M, Greaves MW,. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695-704.
65. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW,. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599-1604.
66. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschläger M, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606-2612.
67. Fiebiger E, Hammerschmid F, Stingl G, Maurer D,. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998; 101: 243-251.
68. Tong LJ, Balakrishnan G, Kochan JP, Kinét JP, Kaplan AP,. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99: 461-465.
69. Sabroe RA, Fiebiger E, Francis DM, Maurer D, Seed PT, Grattan CE, et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002; 110: 492-499.
70. Ferrer M, Nakazawa K, Kaplan AP,. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104: 169-172.
71. Kikuchi Y, Kaplan A,. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109: 114-118.
72. Soundararajan S, Kikuchi Y, Joseph K, Kaplan AP,. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 2005; 115: 815-821.
73. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106: 1001-1006.
74. Schaeffer RC, Gong F, Bitrick MS, Smith TL,. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 1993; 264: 1798-1809.
75. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maranganore JM, Stone SR,. Thrombin functions as an inflammatory mediator through activation of its receptors. J Exp Med 1996; 183: 821-827.
76. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12: 682-687.
77. Natbony SF, Phillips ME, Elias JM, Godfrey HP, Kaplan AP,. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983; 71: 177-183.
78. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP,. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109: 694-700.
79. Kasperska-Zajac A, Sztylc J, Machura E, Jop G,. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy 2011; 41: 1386-1391.
80. Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M,. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010; 40: 875-881.
81. Opal SM,. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 2000; 28 (Suppl): S77-S80.
82. Asero R, Cugno M, Tedeschi A,. Activation of blood coagulation in plasma from chronic urticaria patients with negative autologous plasma skin test. J Eur Acad Dermatol Venereol 2011; 25: 201-205.
83. Asero R, Tedeschi A, Lorini M, Cugno M,. Antihistamines do not inhibit the flare induced by the intradermal injection of autologous plasma in chronic urticaria patients. Eur Ann Allergy Clin Immunol 2009; 41: 181-186.
84. Magen E, Mishal J, Zeldin Y, Feldman V, Kidon M, Schlesinger M, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci 2010; 339: 504-508.
85. Asero R,. D-dimer: a biomarker for antihistamine-resistant chronic urticaria. J Allergy Clin Immunol 2013; 132: 983-986.
86. Rabelo-Filardi R, Daltro-Oliveira R, Campos RA,. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol 2013; 161: 197-204.
87. Kasperska-Zajac A,. Acute-phase response in chronic urticaria. J Eur Acad Dermatol Venereol 2012; 26: 665-672.
88. Marzano AV, Tedeschi A, Fanoni D, Bonanni E, Venegoni L, Berti E, et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol 2009; 160: 266-272.
89. Takahagi S, Mihara S, Iwamoto K, Morioke S, Okabe T, Kameyoshi Y, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010; 65: 649-656.
90. Parslew R, Pryce D, Ashworth J, Friedmann PS,. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30: 1161-1165.
91. Chua SL, Gibbs S,. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005; 153: 216-217.
92. Spring P, Angelillo-Scherrer A, Bigliardi P,. Chronic idiopathic urticaria successfully treated by anticoagulant drugs. Eur J Dermatol 2012; 22: 788-790.
93. Takahagi S, Shindo H, Watanabe M, Kameyoshi Y, Hide M,. Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate. Acta Derm Venereol 2010; 90: 425-426.
94. Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 2009; 31: 668-675.
95. Bossi F, Frossi B, Radillo O, Cugno M, Tedeschi A, Riboldi P, et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 2011; 66: 1538-1545.